Literature DB >> 22731397

Factors associated with relapse in patients with schizophrenia.

Luis San1, Miquel Bernardo, Agustín Gómez, Mario Peña.   

Abstract

OBJECTIVE: To assess risk factors for relapse in patients with schizophrenia attended in daily practice.
METHODS: Patients with schizophrenia admitted consecutively to short-stay/acute-care psychiatric units over a 6-month period were eligible. Variables statistically significant in the univariate logistic regression analysis were then subjected to multivariate analysis.
RESULTS: The study population included 1646 patients (67.6% men). In the univariate analysis, low family support, duration of illness > 5 years, number of previous hospitalizations, cocaine and cannabis consumption, and number of different antipsychotic drug classes were risk factors for relapse. In the multivariate analysis, number of previous hospitalizations (odds ratio [OR] 1.29, 95% confidence interval [CI] 1.21-1.36) and number of different antipsychotics previously used (OR = 1.13, 95% CI 1.03-1.24) were significant predictors of relapse. The absence of cannabis consumption was a protective factor (OR = 0.72, 95% CI 0.58-0.89). Neither adherence to treatment in the previous 3 years nor type of antipsychotic regimen was significantly associated with relapse.
CONCLUSIONS: Number of previous hospitalizations and number of different types of antipsychotic drugs were associated with relapse. Absence of cannabis consumption was a protective factor.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22731397     DOI: 10.3109/13651501.2012.687452

Source DB:  PubMed          Journal:  Int J Psychiatry Clin Pract        ISSN: 1365-1501            Impact factor:   1.812


  9 in total

1.  Predictors of medication adherence among patients with severe psychiatric disorders: findings from the baseline assessment of a randomized controlled trial (Tecla).

Authors:  Ulrike Stentzel; Neeltje van den Berg; Lara N Schulze; Thea Schwaneberg; Franziska Radicke; Jens M Langosch; Harald J Freyberger; Wolfgang Hoffmann; Hans-Jörgen Grabe
Journal:  BMC Psychiatry       Date:  2018-05-29       Impact factor: 3.630

2.  Relapse after abrupt discontinuation of maintenance electroconvulsive therapy during the COVID-19 pandemic.

Authors:  Simon Lambrichts; Kristof Vansteelandt; Bo Crauwels; Jasmien Obbels; Eva Pilato; Jonas Denduyver; Katrien Ernes; Pieter-Paul Maebe; Charlotte Migchels; Lore Roosen; Satya Buggenhout; Filip Bouckaert; Didier Schrijvers; Pascal Sienaert
Journal:  Acta Psychiatr Scand       Date:  2021-06-28       Impact factor: 7.734

3.  Effects of auricular acupressure on body weight parameters in patients with chronic schizophrenia.

Authors:  Han-Yi Ching; Shang-Liang Wu; Wen-Chi Chen; Ching-Liang Hsieh
Journal:  Evid Based Complement Alternat Med       Date:  2012-09-10       Impact factor: 2.629

4.  High relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the People's Republic of China.

Authors:  Jingbo Xiao; Weifeng Mi; Lingzhi Li; Ying Shi; Hongyan Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2015-05-08       Impact factor: 2.570

5.  Determinants and prevalence of relapse among patients with substance use disorders: case of Icyizere Psychotherapeutic Centre.

Authors:  Eric Kabisa; Emmanuel Biracyaza; Jean d'Amour Habagusenga; Aline Umubyeyi
Journal:  Subst Abuse Treat Prev Policy       Date:  2021-02-01

6.  Investigating factors associated with the number of rehospitalizations among patients with schizophrenia disorder using penalized count regression models.

Authors:  Mahya Arayeshgari; Ghodratollah Roshanaei; Ali Ghaleiha; Jalal Poorolajal; Leili Tapak
Journal:  BMC Med Res Methodol       Date:  2022-06-15       Impact factor: 4.612

7.  Effectiveness of More Personalized, Case-Managed, and Multicomponent Treatment for Patients with Severe Schizophrenia Compared to the Standard Treatment: A Ten-Year Follow-Up.

Authors:  Juan J Fernández-Miranda; Silvia Díaz-Fernández; Francisco López-Muñoz
Journal:  J Pers Med       Date:  2022-07-04

8.  Single-blind, randomized controlled trial of effectiveness of Naikan therapy as an adjunctive treatment for schizophrenia over a one-year follow-up period.

Authors:  Hong Zhang; Chenhu Li; Liyu Zhao; Guilai Zhan
Journal:  Shanghai Arch Psychiatry       Date:  2015-08-25

9.  How High? Trends in Cannabis Use Prior to First Admission to Inpatient Psychiatry in Ontario, Canada, between 2007 and 2017.

Authors:  Taylor McGuckin; Mark A Ferro; David Hammond; Shannon Stewart; Bridget Maloney-Hall; Nawaf Madi; Amy Porath; Christopher M Perlman
Journal:  Can J Psychiatry       Date:  2020-12-31       Impact factor: 4.356

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.